392 related articles for article (PubMed ID: 19855306)
1. Characterization of S-glutathionyl hemoglobin in homozygous sickle cell disease.
Thom GG; Kallanagowdar C; Somjee SS; Velez MC; Yu LC; Hempe JM
J Pediatr Hematol Oncol; 2009 Dec; 31(12):895-900. PubMed ID: 19855306
[TBL] [Abstract][Full Text] [Related]
2. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
Rodgers GP
Semin Oncol; 1992 Jun; 19(3 Suppl 9):67-73. PubMed ID: 1379375
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
4. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
Rodgers GP; Dover GJ; Noguchi CT; Schechter AN; Nienhuis AW
N Engl J Med; 1990 Apr; 322(15):1037-45. PubMed ID: 1690857
[TBL] [Abstract][Full Text] [Related]
5. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
[TBL] [Abstract][Full Text] [Related]
6. Mass spectral analysis of asymmetric hemoglobin hybrids: demonstration of Hb FS (alpha2gammabetaS) in sickle cell disease.
Ofori-Acquah SF; Green BN; Davies SC; Nicolaides KH; Serjeant GR; Layton DM
Anal Biochem; 2001 Nov; 298(1):76-82. PubMed ID: 11673898
[TBL] [Abstract][Full Text] [Related]
7. The relationship between fetal hemoglobin and disease severity in children with sickle cell anemia.
Odenheimer DJ; Sarnaik SA; Whitten CF; Rucknagel DL; Sing CF
Am J Med Genet; 1987 Jul; 27(3):525-35. PubMed ID: 2443006
[TBL] [Abstract][Full Text] [Related]
8. Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease?
Segel GB; Simon W; Lichtman MA
Pediatr Blood Cancer; 2011 Jul; 57(1):8-9. PubMed ID: 21480473
[No Abstract] [Full Text] [Related]
9. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Charache S
Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
[TBL] [Abstract][Full Text] [Related]
10. Comparison of radial immunodiffusion and alkaline cellulose acetate electrophoresis for quantitating elevated levels of fetal hemoglobin (HbF): application to evaluating patients with sickle cell disease treated with hydroxyurea.
Schultz JC
J Clin Lab Anal; 1999; 13(2):82-9. PubMed ID: 10102137
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
Rogers ZR
Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
[TBL] [Abstract][Full Text] [Related]
12. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
[TBL] [Abstract][Full Text] [Related]
13. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
[TBL] [Abstract][Full Text] [Related]
15. Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
Kattamis A; Lagona E; Orfanou I; Psichou F; Ladis V; Kanavakis E; Metaxotou-Mavrommati A; Kattamis C
Pediatr Hematol Oncol; 2004 Jun; 21(4):335-42. PubMed ID: 15205096
[TBL] [Abstract][Full Text] [Related]
16. Physiologic decline in fetal hemoglobin parameters in infants with sickle cell disease: implications for pharmacological intervention.
Marcus SJ; Ware RE
J Pediatr Hematol Oncol; 1999; 21(5):407-11. PubMed ID: 10524455
[TBL] [Abstract][Full Text] [Related]
17. Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia.
Lebensburger J; Johnson SM; Askenazi DJ; Rozario NL; Howard TH; Hilliard LM
Am J Hematol; 2011 May; 86(5):430-2. PubMed ID: 21523807
[TBL] [Abstract][Full Text] [Related]
18. Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea.
Lapouméroulie C; Benkerrou M; Odièvre MH; Ducrocq R; Brun M; Elion J
Haematologica; 2005 Mar; 90(3):401-3. PubMed ID: 15749673
[TBL] [Abstract][Full Text] [Related]
19. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia.
Ballas SK; Connes P;
Eur J Haematol; 2018 Dec; 101(6):798-803. PubMed ID: 30204261
[TBL] [Abstract][Full Text] [Related]
20. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
